About the Company
precipio is a cancer diagnostics reference laboratory, delivering the latest in advanced diagnostics and personalized medicine. our goal is to assist oncologists in providing the best care for their patients. at the intersection of academia, cancer research, and diagnostics, we connect physicians with world-renown pathologists at the yale school of medicine. at precipio, our customers and their patients benefit from the most accurate, expert diagnosis. we provide our customers exclusive access to some of the most innovative tests in the field of molecular diagnostics, developed through cutting edge research, and the ongoing pursuit and refinement of the science of personalized medicine.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $PRPO News
Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY
NEW HAVEN, Conn., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that for the full year of 2023, its unaudited revenues have grown ...
Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen® Portfolio of Molecular assays for Cancer
NEW HAVEN, Conn., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc.(NASDAQ: PRPO) announces it has entered into a distribution agreement with Cardinal Health ...
Precipio Inc PRPO
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Precipio, Inc. (PRPO) Stock Historical Prices & Data - Yahoo Finance
*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...
Precipio Announces Christina Valauri joins the Board of Directors
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) is pleased to welcome Christina Valauri to its board of directors effective Jan 1st, 2024. Ms. Valauri is joining Precipio’s ...
PRECIPIO INC. DL-,001 (TGK.MU)
Precipio, Inc. ( NASDAQ:PRPO ) is possibly approaching a major achievement in its business, so we would like to shine ...
Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY
NEW HAVEN, Conn., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that for the full year of 2023, its unaudited revenues have grown from ...
Precipio, Inc.
Precipio, Inc.is a cancer diagnostics and reagent technology company, which provides diagnostic products and services to the oncology market. Its products include ICP, HemeScreen, and IV-Cell ...
Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen® Portfolio of Molecular assays for Cancer
NEW HAVEN, Conn., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces it has entered into a distribution agreement with Cardinal Health for ...
Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that for the full year of 2023, its unaudited revenues have grown from $9.4M in 2022 to $15.2M in 2023, an increase of ...
Precipio, Inc. (PRPO)
Precipio, Inc. ( NASDAQ:PRPO ) is possibly approaching a major achievement in its business, so we would like to shine... Simply Wall St. Celebrations may be in order for Precipio, Inc. ( NASDAQ:PRPO ) ...
Loading the latest forecasts...